GrK inhibitors have already been developed to treat inflammatory diseases, including myocardial infarction35, whereas drugs targeting PAR-1 are already used to block platelet aggregation67, suggesting that the manipulation of GrK–PAR-1 interactions may also benefit AD patients. Here, F2R is linked to Alzheimer disease.